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40.4±17.5 years with 76% males, respectively. Amongst the Hungarian patients 18% 
used none or only topical therapy in the last 12 months, 31% systemic non-bio-
logical treatment and 52% biologicals whereas in Iran 48% of the patients applied 
only topicals and 39% treated with non-biological systematic therapy. Mean EQ-5D, 
DLQI and PASI of the Hungarian and the Iranian sample were 0.69±0.3, 6.29±7.3, 
8.01±10, and 0.62±0.4, 10±6.5, 13±8.3, respectively. In both countries psoriasis of the 
neck and/or décolletage was associated with the greatest HRQOL reduction using 
either instrument (p< 0.05). Regarding clinical types, in Hungary the palmoplan-
tar involvement while in Iran nail psoriasis patients reported the worst general 
HRQOL (mean EQ-5D scores: 0.36±0.3 and 0.47±0.4). Correlation between EQ-5D 
and DLQI was found very similar across the two countries (rs= -0.43- and -0.44, 
p< 0.001), but EQ-5D showed significant correlation with PASI only in Hungary 
(rs= -0.43, p< 0.001). Strong positive correlation was identified between DLQI and 
PASI in both countries but only in those patients who received systemic therapy: 
Iran (rs= 0.72, p< 0.001) and Hungary (systemic non-biological: rs= 0.65, p< 0.001, 
biological: rs= 0.76, p< 0.001). ConClusions: Our results suggest that disease 
severity, treatments, and country-specific differences might lead to variations in 
the relationship between the outcome measures used in psoriasis.
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objeCtives: The Quality of Life in Hand Eczema Questionnaire (QOLHEQ) is a disease-
specific instrument to assess health-related Quality of Life (HRQOL) in hand eczema 
(HE) patients. The QOLHEQ assesses four domains of HRQOL: (a) symptoms, (b) emo-
tions, (c) functioning and (d) treatment/prevention. The QOLHEQ total-score ranges 
from 0-127 points. The aim of this study was to assign bands of the QOLHQ-score 
to an anchor question (AQ) on HE severity to aid the interpretation of the QOLHEQ-
score. Methods: Data was drawn from the German validation study of the QOLHEQ. 
We calculated median, mean and mode of the AQ for 30 categories of the QOLHEQ-
score to devise separate sets of bands. Weighted kappa was calculated in order to 
identify the set of bands with the best agreement between QOLHEQ and AQ. Results: 
Overall n= 316 HE patients were included in the study. Their mean age was 46.7 years 
(SD= 12.9) and 54.1% of the sample were female. With a weighted kappa of 0.54 the 
best agreement was found for the following band: QOLHEQ< 9 = minimal impairment; 
QOLHEQ 9-25 = slight impairment; QOLHEQ 25-58 = moderate impairment; QOLHEQ 
59-79 = severe impairment; QOLHEQ> 79 = very severe impairment. ConClusions: 
This is the first study which uses an anchor-based approach in order to devise a 
banding for the QOLHEQ-score. This banding represents a standardized means of 
interpreting the QOLHEQ total score. Further studies are needed to explore which 
banding may be adequate for different language version of the QOLHEQ.
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faCtorS Conditioning HealtH related Quality of life in PatientS 
witH PSoriaSiS in euroPe: a SyStematiC review of tHe literature
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objeCtives: To identify conditioning factors of Health Related Quality of Life 
(HRQoL) of patients with psoriasis as reported in the literature in the last 5 years 
in Europe. Methods: Electronic databases [PubMed, ISI-WOK, Cochrane Library, 
MEDES, CSIC-IME, IBECS] and grey literature [Google Scholar], were searched to 
identify studies written in English or Spanish on HRQoL in patients with psoriasis, 
published in Europe between January 1, 2009 and December 31, 2013. Bibliographic 
references were hand searched. Editorials, letters, commentaries, opinion papers 
and studies related to specific treatments were excluded. Results: 27 stud-
ies accomplished the inclusion criteria. Most of the publications (66.7%, n= 18) 
were cross-sectional studies; 25.9% (n= 7) had a prospective design while 7.4% 
(n= 2) were retrospective. 12 studies analyzed the relation between HRQOL and 
demographic characteristics, determining in 75% and 50% of them, there was a 
relation between sex (women) and age (younger patients) with poorer HRQoL. 
3 publications demonstrated the HRQoL impairment associated with visibility of skin 
lesions. 4 studies appraised the relationship between disease activity and HRQoL 
determining a more compromised HRQOL in those patients with active psoriasis. 
Disease Severity was the most frequent assessed factor, being studied in 13 publica-
tions, describing in 92% of them that patients with higher PASI had worse HRQoL. 2 
articles indicated that disease symptoms as skin discomfort and pruritus were ele-
ments that negatively influenced the HRQoL of these patients. Emotional disturbances 
were identified as predictors of poorer HRQOL in 5 studies. 3 publications determined 
that the use of biologic therapy contributed to improve HRQoL. ConClusions: 
HRQoL has been broadly addressed in patients with psoriasis in Europe. Several 
disease- and patient-related factors contributed to its deterioration. Therapeutic 
measures with proved effectiveness in controlling disease symptoms and reducing 
PASI should be considered in patients with severe disease who have a relation with 
poorer HRQoL.
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(Greece) to 42.8 (Germany) revealing an acceptable perception of HRQoL. Sleep, itch-
ing/embarrassment and mental health were the HRQoL dimensions most impaired. 
Patients taking prescription drugs were more satisfied than those taking over the 
counter (p< 0.01). Severely ill patients were willing to change therapies if new, more 
effective alternatives became available (p< 0.05). Only 1 study assessed the costs of 
CU in Europe while another one described the use of medical resources. CU total 
cost in France was € 2,139.48 per patient/year. Patients lost 2.2 working days/month, 
being productivity losses 92% of total costs. CU patients were mostly cared for a 
dermatologist according to findings in Germany. A mean of 11.7 (SD: 11.5) visits/
month to the dermatology clinic were reported. ConClusions: PROs and costs 
in CU are infrequently addressed in the literature. Findings show patients reduced 
HRQoL and their willingness for more effective therapies. Frequent medical visits 
and loss of productivity make CU a burdensome disease in European countries.
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a review of Patient rePorted outComeS (ProS) in PSoriaSiS aCCording 
to tHe food and drug adminiStration (fda) Pro guidanCe Criteria
Cheng R.
Covance Market Access Services, Inc., San Diego, CA, USA
objeCtives: Psoriasis is a chronic inflammatory skin condition that affects an 
estimated 4.5 to 7.5 million people in the United States. Numerous clinical trials 
have been conducted in psoriasis, many of which have included general derma-
tologic or psoriasis-specific PROs as study outcome measures. Commonly used 
PROs in these trials include the Dermatology Life Quality Index (DLQI), Psoriasis 
Disability Index (PDI), Psoriasis Life Stress Inventory (PLSI), Psoriasis Quality of Life 
Questionnaire (PQOL-12), and Skindex. This study assessed how well the develop-
ment and validation process of psoriasis-specific PROs align with the FDA PRO 
guidance. Methods: We reviewed the development and validation studies of the 
five PROs to assess if they align with the FDA PRO guidance criteria with regard to: 
(1) content validity, including patient input in concept elicitation, item generation, 
and cognitive debriefing; and (2) psychometric testing, including construct validity, 
internal-consistency and test-retest reliability, and responsiveness. Results: The 
PDI was developed without patient input in terms of concept elicitation, item gen-
eration, or cognitive debriefing. Variability and oftentimes inadequately documented 
evidence of patient input for concept elicitation, item generation, and cognitive 
debriefing were observed for the other four PROs. Test-retest reliability was not 
evaluated in the PLSI. Evidence of responsiveness was not available for three of the 
PROs. ConClusions: Based on this review, additional qualitative and quantitative 
research is needed to eliminate the identified gaps before these PROs could fulfill 
the FDA guidance for inclusion as a measure for a PRO label claim.
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objeCtives: The aim of this global survey was to evaluate the management of 
wet age-related macular degeneration (wAMD) from a patient/caregiver perspec-
tive. Methods: Patients with a wAMD diagnosis and current or prior use of intravit-
real injections and caregivers from nine countries (Australia, Brazil, Canada, France, 
Germany, Italy, Japan, Spain, and the UK) completed a questionnaire. Results: 910 
patients and 890 caregivers were surveyed. 55% of patients had wAMD in 1 eye and 
64% had been receiving intravitreal injections for > 1 year. Many caregivers were a 
child/grandchild of the patient (47%), or partner (23%); only 7% were a professional 
caregiver. Most (73%) patients visited a health care professional (HCP) within 1 
month of first noticing a change in vision; 41% of patients who delayed visiting 
a HCP thought the symptoms would resolve. Following diagnosis, 54% of patients 
began treatment immediately, and a further 37% scheduled an appointment within 
1–3 weeks. 52% of patients reported a temporary improvement or stabilization in 
vision as a result of current treatment, and 22% reported a return to pre-diagnosis 
vision or that their vision was still improving. Most patients and caregivers reported 
a number of obstacles in managing wAMD, including the treatment itself (35% and 
39%, respectively), treatment costs (28% and 29%), and finding the right treatment 
options (27% and 31%). Additionally, 27% of caregivers found the patient’s treat-
ment extremely inconvenient with 57% of employed (non-professional) caregivers 
having to take time off work or miss personal obligations. 16% of patients missed 
a HCP appointment because their caregiver was unable to take them (26%), fear of 
injections (21%), illness (19%), forgetfulness (15%), inconvenience (10%), costs (6%), 
and discomfort of injections (3%). ConClusions: Many patients and caregivers 
identified a number of obstacles in managing wAMD. These included the treatment 
itself (patients and caregivers) and loss of productivity (non-professional caregivers).
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a ComaPrative CroSS-SeCtional Study on HealtH-related Quality of 
life in PSoriaSiS from Hungary and iran
Moradi M., Rencz F.
Corvinus University of Budapest, Budapest, Hungary
objeCtives: To compare health-related quality of life (HRQOL) of Hungarian and 
Iranian psoriasis patients and to analyze possible differences in the relationship 
between EuroQol 5 dimensions (EQ-5D), Dermatology Life Quality Index (DLQI) 
and Psoriasis Area and Severity Index (PASI). Methods: Same cross-sectional 
questionnaire survey was carried out in two countries. Altogether 200 adult pso-
riasis patients enrolled from two Hungarian university clinics and 62 from an 
Iranian clinic. Besides HRQOL assessment, data on demographics, applied treat-
ments, affected body sites and clinical types were collected. Results: Mean age 
of the Hungarian and Iranian patients were 51.2 ±12.9 years with 69% males, and 
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fabriCation of voriConazole Solid liPid nanoPartiCleS for effeCtive 
oCular delivery
Kumar R., Sinha V.R.
UIPS, Panjab University, Chandigarh, India
objeCtives: Preparation of Voriconazole (VCZ) solid lipid nanoparticles (SLNs) for 
effective ocular delivery for the treatment of fungal keratitis. Methods: SLNs were 
prepared by solvent emulsification technique using Compritol (lipid), Pluronic F-68 
(surfactant) and sodium taurocholate (co-surfactant). Characterization of SLNs was 
performed by size measurement, in-vitro release, ex-vivo corneal permeation stud-
ies and in-vitro antifungal activity. Results: Particle sizes were found in the range 
of 150-300 depending upon lipid/Smix ratio with good zeta potential. Entrapment 
efficiency of SLNs was found between 40-60% with sustained in vitro drug release 
(> 70% in 12h). The ex-vivo corneal permeation studies exhibited good ocular per-
meation of VCZ from SLNs. Ex-vivo study also supports good ocular permeation of 
VCZ from SLNs when compared with drug suspension. Further, in-vitro antifungal 
activity exhibited the potential of VCZ SLNs. ConClusions: The sustained release 
property with good corneal permeation of VCZ from SLNs encourages its applica-
tion for in-vivo studies and hence could be proposed as an effective carrier for 
ophthalmic administration.
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tHe analySiS of dental Care in ukraine at tHe regional level
Zaliskyy O., Shcherba P., Zalis’ka O.
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
objeCtives: The structure of the overall incidence diseases the mouth and teeth 
morbidity occupy the third place in Ukraine. Thus 99% of the patients served in 
outpatient clinics institutions. The structure of diseases requiring hospitalization 
(approximately 1% of patients), the top spot is occupied odontogenic inflammatory 
diseases and injuries of the maxillofacial face. Methods: In Ukraine, the avail-
ability of dentists is 4.0 per 10 000 population and 4.5 per 10 000 children. We have 
analyzed the statistical data of the Lviv Regional Department of Health. We found 
that 98% of the population have dental problems. Prevalence of dental caries, tempo-
rary occlusion in 6-years children reached 87.9%, a 12-year-olds - 72.3%. Prevalence 
of chronic catarrhal gingivitis among adolescents aged 12-15 years ranged 70-98% 
and teeth abnormalities in children 7-18 years more than 80%. In Ukraine every-
one requires a prosthetics after 50 years. Results: Main social burden have the 
dental institutions of the state and municipal property. By 2013 there were about 
1.5 million causes to the dental care. We determined that in Lviv region on the 
basis of licenses to practice medicine in dentistry are 248 dentists, who working 
in cities and towns, and only about 10% - in rural areas. From 196th private den-
tal surgeries 89 are situated in the regional center. Danylo Halytsky Lviv National 
Medical University opened and acting university Dental Center from 2012, where 
dentists had treated about 400 000 people, including more than 172 000 children 
each year. Such preventive examinations make it possible to carry out monitoring 
as indicators of dental public health field, to identify the most important risk fac-
tors for dental diseases. ConClusions: The management and pharmacoeconomic 
studies of dental care, identifying optimal funding for state and municipal health 
care institutions for cost-effectiveness use of state funds.
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dental Care uSe and aSSoCiated faCtorS among PeoPle witH 
rHeumatoid artHritiS: a nationwide, PoPulation-baSed, ProPenSity 
SCore-matCHed follow-uP Study
Chen Y.T.
Yang-Ming University, Taiwan, Taiwan
objeCtives: Patients with RA suffer from a higher risk of periodontal attachment 
loss and increased oral inflammation. There were few studies to access the utiliza-
tion of dental care among RA in the Taiwan. The purpose is identify realize analyze 
and discuss the dental use of diabetic patients, and the association between the risk 
of rheumatoid arthritis (RA) and a history of periodontitis. Methods: retrospective 
cohort studybased on the nationwide, population-based, NHIB used administra-
tive data, case group consisted of 5,506 (age ≥ 18 years) patients with rheumatoid 
arthritis (RA group) as the study group and 22,024 patients without RA attending 
the Outpatient wing of Department of General Medicine formed the control group 
(NRA group). Matched for Age, gender and RUB, Both groups were matched on 1:4.  
Results: More advanced forms of periodontitis were found in RA patients com-
pared with controls. The results showed that RA patients (66.9% of RA) had 5-years 
utilization rate of dental care than non-RA patients (13.9% of non-RA). However, 
people have RA or not, the characteristics of dental use were similar. Only has the 
gender aspects to differ from, when the male suffered from RA, the utilization of 
dental care were not different with the female. ConClusions: we propose that the 
consulting rheumatologists inform the patients that they have a higher risk of peri-
odontal. this study demonstrates an association between periodontitis and incident 
RA. And the study is limited to lack of BMI, smoking, alcohol status.
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maCular oedema due to retinal vein oCCluSion metHodS for tHe 
identifiCation of treatment guidelineS and areaS of unmet CliniCal 
needS by meanS of SyStematiC review
Patel A.S.
Abacus International, Bicester, UK
objeCtives: Retinal vein occlusion (RVO) causes macular oedema (MO), which 
can lead to vision loss. The present study sought to identify treatment guidelines 
internationally by conducting a systematic review and extensive hand searches. 
The aims were to i) develop a systematic methodology for the identification of 
such guidelines ii) review the guidelines and treatment pathways identified in 
order to propose optimal positioning for an hypothetical intervention for the treat-
ment of MO in RVO, and iii) to identify areas of unmet clinical needs. Methods: 
objeCtives: To assess the cost-effectiveness of nutritional support (high protein 
supplementary diet) versus standard care (regular hospital diet) in preventing pres-
sure ulcers in hospitalised patients at high risk of pressure ulcers and malnutri-
tion. Further, to evaluate the need and value of additional research using value of 
information analysis. Methods: Analyses were undertaken from the perspective 
of the State health department in Queensland, Australia, using a Markov decision 
model. Evidence for the relative risk (RR) was estimated from a meta-analysis of 
randomised controlled trials; other parameters were systematically identified from 
the literature to populate the model. The incremental net monetary benefit (INB) 
was calculated and a probabilistic sensitivity analysis using Monte Carlo simulation 
was conducted. The expected value of perfect information (EVPI), expected value 
of perfect parameter information (EVPPI), expected value of sample information 
(EVSI), expected total cost of additional research, expected net benefit of sampling 
(ENBS), and the return on investment (ROI) were calculated for an estimated popula-
tion of 125,000 over ten years. Results: At a willingness-to-pay of AU$ 50,000 per 
quality-adjusted life year, the INB was AU$ 530, with a probability of 84% for nutri-
tional support to be the preferred intervention. The population EVPI was AU$ 4.75 
million, the highest EVPPI was for RR at AU$ 2.25 million. For a future randomised 
study investigating the RR of the two interventions, the ENBS would be maximised 
at AU$ 380,000 with 1,200 patients in each arm; from an EVSI of AU$1.6 million and 
total study cost of AU$ 1.2 million. The expected ROI would be 32%. ConClusions: 
Nutritional support is cost-effective in preventing pressure ulcers in high risk hos-
pitalised patients; however, there is uncertainty surrounding the decision and the 
value of this uncertainty is high. A future clinical trial to resolve this uncertainty 
is worthwhile.
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tHe imPaCt of tHe german drg-SyStem on PoliCy deCiSion making in 
ent
Fichtenbauer M., Kosaner M., Urban M.
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objeCtives: The German diagnosis-related groups (G-DRG) have been introduced 
as a reimbursement system for in-patient care. The aim of this study was to report 
on clinic-based data available from the G-DRG browser regarding the impact of 
middle ear implantation as a basis for future health care decision making in 
ear, nose and throat medicine (ENT). Methods: Using a clinical algorithm, the 
unevaluated D23Z database from 2012 was analyzed to determine epidemiologi-
cal characteristics of patients with different types of hearing losses and receiving 
middle ear implants (MEI). All ICD-10 Codes used for the diagnosis of conduc-
tive (CHL), mixed (MHL) or sensorineural hearing loss (SNHL) were extracted. The 
number of MEI cases reported in the D23Z was analyzed regarding Patient Clinical 
Complexity Level (PCCL), age, sex and duration of stay. The incidence of MEI 
candidates to the total number of ICD-10 codes and per indication were calcu-
lated. Results: According to the D23Z, approximately 30`000 individuals admitted 
to ENT clinics were diagnosed with a hearing loss. About 38% suffered from CHL, 
8% suffered from MHL and 48% suffered from SNHL. The proportion of patients 
who received a MEI per indication were respectively 0.8% for SNHL, 8% for MHL 
and 1% for CHL. Overall, about 466 (1%) patients received a MEI. 49.8% of them 
were men and 50.2% were women. Children aged as young as 1-2 years could 
also receive treatment. All patients had normal-term stay in hospitals with no 
comorbidities or complications (PCCL < 4 in 99.2% of cases) The incidence of MEI 
to the ENT patient base and the German population were respectively 15.5/1,000 
and 0.6/100,000. ConClusions: The overall number of middle ear implantations 
compared to standard treatments is quite low. Analyzing data on MEI available 
from highly-developed DRG systems can be used by other countries for policy 
decision making in ENT.
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underStanding trendS in oPHtHalmologiSt Patient SeleCtion and 
Care baSed on PatternS of billing
Culp J.L.1, Connelly N.1, Kristopik J.1, Doyle J.J.2
1Quintiles Consulting, Durham, NC, USA, 2Quintiles, Hawthorne, NY, USA
The recent U. S. release of Medicare Part B billing data provides unprecedented 
insight into a health care system that reimbursed $77 billion in 2012. Of the 100 
physicians receiving the greatest payments, nearly half were ophthalmologists.  
objeCtives: Examine ophthalmologist trends in patient selection and care, 
and implications on system value delivery, based on Medicare and other 
data. Methods: We examined aggregate and line-item data, comparing the 
100 highest billing ophthalmologists to each other, and to the remaining 16,971, 
identifying patterns in services billed, beneficiaries served, service location, and 
dollars billed, allowed and paid. We also compared volume and cost of a key office-
based code (J2778: Ranibizumab injection) to a key facility-based code (67042: 
vitrectomy for macular hole), and incorporated epidemiology data to understand 
provider incentives and drivers of care. Results: Ophthalmologists represented 
2% of all practitioners billing Part B, but received 7% of reimbursement; the Top 
100 billing ophthalmologists accounted for 0.6% of ophthalmologists billing, but 
received 8.8% of payments; disparities between Top 100 billers and non-Top 100 
include: variety of patients treated, percent of charges reimbursed, and practice 
location; high volume J2778 performers were much more likely to be Top 100 bill-
ers than were high performers of 67042; and based on prevalence among those 
65 and older, a significantly greater percentage of beneficiaries with wet AMD 
received treatment than did beneficiaries with macular hole. ConClusions: 
A large portion of payments were received by relatively few ophthalmologists, 
whose practices demonstrate disparities in variety and volume of procedures 
over non-top billers; incentives—some financial—may be factors that contribute 
to greater treatment of wet AMD than of macular hole; and a focus on conducting 
high-reimbursement services may drive disproportionate system costs. Greater 
transparency may drive changes in practitioner behavior, and reduce unnecessary 
health care system costs.
